MTCR addendum:
1) MTCR’s MET642 dataset just released is possibly the worst I’ve ever seen for a trial where the sponsor claimed the results were “encouraging.” At the high dose, there was no efficacy, but there was a sharp increase in LDL. Taking this drug for NASH very likely has a negative effect on MACE, compared to placebo.
2) FXR agonism for NASH is a discredited idea, for all practical purposes.
3) Pivoting MET642 to IBD might conceivably work, but it looks like a case of Zebra’s Law.
All told, the 50% drop in AH trading is justified, IMO.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”